MC² Research Program News & Announcements

The Connor Initiative, a multimillion dollar gift from the Holveck Family, will support precision therapeutics for osteosarcoma and rare cancers.

This three-year, $6.4 million gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.

The Center for Precision Medicine for High-risk Pediatric Cancer Frontier Program builds upon ongoing precision medicine efforts across CHOP departments to define and expand treatment options.

Learn about a technique to analyze large datasets, preclinical results that show safety and efficacy of a drug that could help children with high-risk neuroblastoma, and a milestone in the CORSICA project that seeks to cure rare sinonasal cancers.

This week’s research news roundup includes accolades for our scientists and the spaces they work in.

A U.S. Department of Defense grant will support CHOP researchers in their study of noninvasive methods to diagnose mitochondrial diseases.

This week’s In the News highlights research on mitochondrial disease, acute lymphoblastic leukemia, type 2 diabetes, and sleep apnea.

Whole genome sequencing for thousands of brain tumor samples will give the D³b team insight into devastating pediatric cancers.

A rare disease hack-a-thon leads to an unusual collaboration between D3b’s bioinformaticians, including Adam Resnick, PhD, and American Airlines’ software engineers.

Marni Falk, MD, and Adam Resnick, PhD, to lead the Mitochondria and Cancer Connections (MC²) Research Program, a new CHOP research initiative.